Skip to content
DataLookout
Menu

CLOSE-3NCT05724446

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

StatusRecruiting
PhasePhase 3
SponsorSalvat
Primary completion (estimated)

At risk: Primary completion moved at least 6 years 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 31, 2025 to Nov 18, 2032 Show 6 more changesShow less
    • Eligibility criteria expanded, about 25 words
    • Trial status changed: Unknown → Recruiting
    • Study completion pushed from Dec 31, 2025 to Dec 31, 2032
    • Start date pushed from Dec 12, 2022 to Jan 4, 2023
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary and study completion dates: Aug 31, 2024 to Dec 31, 2025
    • Secondary endpoints: details revised at 1 of 2 entries
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Assess the safety of Clobetasol propionate ophthalmic nanoemulsion, 0.05% treatment after cataract surgery in pediatric population 0 to 3 years of age, compared to Prednisolone acetate ophthalmic suspension, 1%.
Timeframe: Day 43

Secondary (2)

Assess the efficacy on ocular inflammation of Clobetasol propionate ophthalmic nanoemulsion, 0.05% treatment after cataract surgery in pediatric population 0 to 3 years of age, compared to Prednisolone acetate ophthalmic suspension, 1%.
Assess the efficacy on pain of Clobetasol propionate ophthalmic nanoemulsion, 0.05% treatment after cataract surgery in pediatric population 0 to 3 years of age, compared to Prednisolone acetate ophthalmic suspension, 1%.

Arms and interventions

Clobetasol propionateExperimental

One drop of Clobetasol propionate ophthalmic nanoemulsion, 0.05% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.

Prednisolone acetateActive comparator

One drop of Prednisolone ophthalmic suspension, 1% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.

Drugs: Clobetasol Propionate, Prednisolone acetate ophthalmic suspension, 1%

Sites

1 site in 1 country

  • Hospìtal Sant Joan de DeuBarcelona, Barcelone, Spain